Skip to Primary Navigation Skip to Site Navigation Skip to Main Content All 3M.com Site Map

New Clinical Data Highlights Efficacy, Efficiency of 3M™ Conix DPI


New Clinical Data Highlights Efficacy, Efficiency of 3M™ Conix DPI
Tests show results comparable to Advair Diskus®

ST. PAUL, Minn. – February 16, 2011 – 3M Drug Delivery Systems has completed a clinical study of its Conix™ Dry Powder Inhaler (DPI) in asthmatic patients, with results showing the device can achieve bronchodilator efficacy comparable to the Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) while using less drug. The findings hold significant potential for pharmaceutical companies seeking an efficient delivery system for inhalation therapy.

The study compared the Conix DPI with the Advair Diskus 100/50 in the delivery of a combination therapy (fluticasone propionate and salmeterol xinafoate). Seventeen patients with mild to moderate asthma received two treatments separated by 7 to 16 days, according to a randomized, two-period crossover design. The reference treatment was one inhalation from an Advair Diskus, labeled to deliver 100 µg fluticasone propionate and 50 µg salmeterol base equivalent. Results from this treatment were compared with the test treatment of one inhalation from the Conix DPI, which contained a significantly lower quantity of each drug per pre-metered dose.

Results of the study showed that the Conix DPI achieved a similar improvement in pulmonary function as compared with the Advair Diskus. Additionally, the study demonstrated that pulmonary delivery of a combination formulation from the Conix DPI device was safe and well tolerated, and patients reported the Conix DPI device was easy to use.

The Conix DPI is designed to deliver a higher respirable (more efficient) dose and a smaller non-respirable (less swallowed) dose to patients. The Conix DPI works by using an innovative reverse-flow cyclone technology to deagglomerate and aerosolize drug particles. The inhaler’s design allows formulation flexibility and protection from moisture ingress, and is engineered to increase the effectiveness of energy transfer from the patient’s inspiration to the drug formulation.

“The 3M Conix DPI shows significant advantages over currently available products,” said Joyce Eyerly, DPI Business Director for 3M Drug Delivery Systems. “By efficiently delivering the therapeutic drug to the patient’s lung, and less non-therapeutic drug to the mouth and throat, the Conix DPI can provide effective treatment with the potential for fewer side effects.”

“Increased patient satisfaction and compliance, as well as reduced drug costs are very important benefits to the pharmaceutical industry,” said Eyerly. “The Conix DPI presents a solution to many of the challenges found with currently available inhalers.”

The Conix DPI is currently available for use with marketed molecules as well as new chemical entities. For more information, contact Global DPI Business Director, Joyce Eyerly at jkeyerly@mmm.com or (651) 733-1357.

About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M’s inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process. This depth of resources is one reason why more than 50 percent of all metered-dose inhalers worldwide and 80 percent of all transdermal systems in the United States utilize 3M drug delivery technology. For more information, please visit www.3M.com/dds or call 1-800-643-8086.

About 3M
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $27 billion in sales, 3M employs about 80,000 people worldwide and has operations in more than 65 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.

3M is a trademark of 3M Company.
Advair Diskus® is a registered trademark of GlaxoSmithKline

Contact:
Michael Gugala
Karwoski & Courage
(612) 342-9604
m.gugala@creativepr.com

Mary Kokkinen
3M Public Relations and Corporate Communications
(651) 733-8806
mckokkinen@mmm.com

3M Drug Delivery Systems
3M Center, Bldg 275-3E-10
St. Paul, MN 55144

Back